Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Jachs

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|March 28, 2026
Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort studyMichael Schwarz, Marlene Hintersteininger, Caroline Schwarz, et al.
Hepatology (Baltimore, Md.)|January 8, 2025
Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter studyMartin A Kabelitz, Lukas Hartl, Golda Schaub, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2026
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical OutcomesBenedikt Silvester Hofer, Thomas Perkmann, Ksenia Brusilovskaya, et al.
United European Gastroenterology Journal|December 7, 2021
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosisMathias Jachs, Teresa Binter, Caroline Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Hepatology (Baltimore, Md.)|January 16, 2025
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Hepatology (Baltimore, Md.)|July 30, 2024
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
JHEP Reports : Innovation in Hepatology|March 28, 2026
Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort studyMichael Schwarz, Marlene Hintersteininger, Caroline Schwarz, et al.
Hepatology (Baltimore, Md.)|January 8, 2025
Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter studyMartin A Kabelitz, Lukas Hartl, Golda Schaub, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2026
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical OutcomesBenedikt Silvester Hofer, Thomas Perkmann, Ksenia Brusilovskaya, et al.
United European Gastroenterology Journal|December 7, 2021
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosisMathias Jachs, Teresa Binter, Caroline Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Hepatology (Baltimore, Md.)|January 16, 2025
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Hepatology (Baltimore, Md.)|July 30, 2024
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cureGeorg Semmler, Sonia Alonso López, Monica Pons, et al.
Pageof 12